New targets and strategies in treatment of metastatic gastric cancer.

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-17 DOI:10.1080/14796694.2025.2547562

Melih Simsek, Haci Mehmet Turk

{"title":"New targets and strategies in treatment of metastatic gastric cancer.","authors":"Melih Simsek, Haci Mehmet Turk","doi":"10.1080/14796694.2025.2547562","DOIUrl":null,"url":null,"abstract":"Introduction: Gastric cancer is a common type of cancer and one of the leading causes of cancer-related deaths. Unfortunately, the number of cases has been rising in recent years. Since this cancer often does not show symptoms in its early stages, most people are diagnosed when the disease is already advanced (stage 3 or 4). At this stage, survival rates are low, with most patients living about 12 months on average.Treatment options: For advanced gastric cancer, the most commonly used treatments are chemotherapy combinations that include oxaliplatin and fluoropyrimidine. Another option is irinotecan, which can be used instead of oxaliplatin. However, older drugs like anthracyclines and docetaxel are no longer widely used. A newer combination of oxaliplatin, fluoropyrimidine, leucovorin, and docetaxel has fewer side effects compared to older treatments.Recent advances: In recent years, researchers have discovered new ways to target gastric cancer. These include therapies that combine antibodies with drugs, therapies that use multiple antibodies, and immunotherapies that help the immune system fight cancer. These new treatments, when added to chemotherapy, offer hope for improving survival rates in people with advanced gastric cancer.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2931-2940"},"PeriodicalIF":2.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439571/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2547562","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Gastric cancer is a common type of cancer and one of the leading causes of cancer-related deaths. Unfortunately, the number of cases has been rising in recent years. Since this cancer often does not show symptoms in its early stages, most people are diagnosed when the disease is already advanced (stage 3 or 4). At this stage, survival rates are low, with most patients living about 12 months on average.

Treatment options: For advanced gastric cancer, the most commonly used treatments are chemotherapy combinations that include oxaliplatin and fluoropyrimidine. Another option is irinotecan, which can be used instead of oxaliplatin. However, older drugs like anthracyclines and docetaxel are no longer widely used. A newer combination of oxaliplatin, fluoropyrimidine, leucovorin, and docetaxel has fewer side effects compared to older treatments.

Recent advances: In recent years, researchers have discovered new ways to target gastric cancer. These include therapies that combine antibodies with drugs, therapies that use multiple antibodies, and immunotherapies that help the immune system fight cancer. These new treatments, when added to chemotherapy, offer hope for improving survival rates in people with advanced gastric cancer.

查看原文本刊更多论文

转移性胃癌治疗的新靶点和新策略。

胃癌是一种常见的癌症类型，也是癌症相关死亡的主要原因之一。不幸的是，近年来病例数量一直在上升。由于这种癌症在早期阶段通常没有症状，大多数人在疾病已经晚期（第3或第4阶段）时被诊断出来。在这个阶段，存活率很低，大多数患者平均存活约12个月。治疗选择：对于晚期胃癌，最常用的治疗方法是包括奥沙利铂和氟嘧啶的化疗组合。另一种选择是伊立替康，它可以代替奥沙利铂。然而，像蒽环类药物和多西紫杉醇这样的老药已不再广泛使用。与旧的治疗方法相比，奥沙利铂、氟嘧啶、亚叶酸蛋白和多西紫杉醇的新组合副作用更少。近年来，研究人员发现了针对胃癌的新方法。这些疗法包括将抗体与药物结合起来的疗法，使用多种抗体的疗法，以及帮助免疫系统对抗癌症的免疫疗法。这些新疗法与化疗相结合，为提高晚期胃癌患者的生存率带来了希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.